<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/935B2919-2093-4FB9-A5D4-59F746D5235A"><gtr:id>935B2919-2093-4FB9-A5D4-59F746D5235A</gtr:id><gtr:name>University of California, Irvine</gtr:name><gtr:address><gtr:line1>UCI</gtr:line1><gtr:postCode>92697</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A6C2759-BD3E-444A-8E97-CB1C0205626B"><gtr:id>4A6C2759-BD3E-444A-8E97-CB1C0205626B</gtr:id><gtr:name>RAND Boston</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7D5BF3BA-A5DB-45D8-9B37-E142494AE3CE"><gtr:id>7D5BF3BA-A5DB-45D8-9B37-E142494AE3CE</gtr:id><gtr:name>Centre For Movement Disorders</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F417BE31-D70C-4AEB-8A1D-273C23D5FBCD"><gtr:id>F417BE31-D70C-4AEB-8A1D-273C23D5FBCD</gtr:id><gtr:name>Ulm University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B4CD670-EFA7-4A29-8208-6EE0C7AE6545"><gtr:id>3B4CD670-EFA7-4A29-8208-6EE0C7AE6545</gtr:id><gtr:name>Shire Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/96EFA8D6-9087-45CB-B5F1-FFAFE8D3BE64"><gtr:id>96EFA8D6-9087-45CB-B5F1-FFAFE8D3BE64</gtr:id><gtr:name>Sangamo Biosciences, Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA747E5D-BCF1-4BA9-A385-A89049293C2E"><gtr:id>FA747E5D-BCF1-4BA9-A385-A89049293C2E</gtr:id><gtr:name>IRBM Promidis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9040505D-32E9-4685-AE24-6609146B7092"><gtr:id>9040505D-32E9-4685-AE24-6609146B7092</gtr:id><gtr:name>Biofocus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/277C881F-47F0-414A-A3B3-AEDA776E6528"><gtr:id>277C881F-47F0-414A-A3B3-AEDA776E6528</gtr:id><gtr:name>CHDI Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F06E2300-1034-4556-912C-36C6D454F922"><gtr:id>F06E2300-1034-4556-912C-36C6D454F922</gtr:id><gtr:name>California Institute of Technology</gtr:name><gtr:address><gtr:line1>1200 East California Boulevard</gtr:line1><gtr:postCode>91125</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D8E23AC-4EC9-4C77-B36D-26A22549E85F"><gtr:id>4D8E23AC-4EC9-4C77-B36D-26A22549E85F</gtr:id><gtr:name>WAVE Life Sciences</gtr:name><gtr:address><gtr:line1>733 Concord Avenue</gtr:line1><gtr:postCode>02138</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6AD0BD31-C238-4411-8CFD-2ACEFAFE8C3C"><gtr:id>6AD0BD31-C238-4411-8CFD-2ACEFAFE8C3C</gtr:id><gtr:name>Leverndale Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8F41604A-4001-4CBF-BE9A-EE225EEF113F"><gtr:id>8F41604A-4001-4CBF-BE9A-EE225EEF113F</gtr:id><gtr:name>Isis Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/935B2919-2093-4FB9-A5D4-59F746D5235A"><gtr:id>935B2919-2093-4FB9-A5D4-59F746D5235A</gtr:id><gtr:name>University of California, Irvine</gtr:name><gtr:address><gtr:line1>UCI</gtr:line1><gtr:postCode>92697</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A6C2759-BD3E-444A-8E97-CB1C0205626B"><gtr:id>4A6C2759-BD3E-444A-8E97-CB1C0205626B</gtr:id><gtr:name>RAND Boston</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7D5BF3BA-A5DB-45D8-9B37-E142494AE3CE"><gtr:id>7D5BF3BA-A5DB-45D8-9B37-E142494AE3CE</gtr:id><gtr:name>Centre For Movement Disorders</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F417BE31-D70C-4AEB-8A1D-273C23D5FBCD"><gtr:id>F417BE31-D70C-4AEB-8A1D-273C23D5FBCD</gtr:id><gtr:name>Ulm University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B4CD670-EFA7-4A29-8208-6EE0C7AE6545"><gtr:id>3B4CD670-EFA7-4A29-8208-6EE0C7AE6545</gtr:id><gtr:name>Shire Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/96EFA8D6-9087-45CB-B5F1-FFAFE8D3BE64"><gtr:id>96EFA8D6-9087-45CB-B5F1-FFAFE8D3BE64</gtr:id><gtr:name>Sangamo Biosciences, Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA747E5D-BCF1-4BA9-A385-A89049293C2E"><gtr:id>FA747E5D-BCF1-4BA9-A385-A89049293C2E</gtr:id><gtr:name>IRBM Promidis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9040505D-32E9-4685-AE24-6609146B7092"><gtr:id>9040505D-32E9-4685-AE24-6609146B7092</gtr:id><gtr:name>Biofocus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/277C881F-47F0-414A-A3B3-AEDA776E6528"><gtr:id>277C881F-47F0-414A-A3B3-AEDA776E6528</gtr:id><gtr:name>CHDI Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F06E2300-1034-4556-912C-36C6D454F922"><gtr:id>F06E2300-1034-4556-912C-36C6D454F922</gtr:id><gtr:name>California Institute of Technology</gtr:name><gtr:address><gtr:line1>1200 East California Boulevard</gtr:line1><gtr:postCode>91125</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D8E23AC-4EC9-4C77-B36D-26A22549E85F"><gtr:id>4D8E23AC-4EC9-4C77-B36D-26A22549E85F</gtr:id><gtr:name>WAVE Life Sciences</gtr:name><gtr:address><gtr:line1>733 Concord Avenue</gtr:line1><gtr:postCode>02138</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6AD0BD31-C238-4411-8CFD-2ACEFAFE8C3C"><gtr:id>6AD0BD31-C238-4411-8CFD-2ACEFAFE8C3C</gtr:id><gtr:name>Leverndale Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F41604A-4001-4CBF-BE9A-EE225EEF113F"><gtr:id>8F41604A-4001-4CBF-BE9A-EE225EEF113F</gtr:id><gtr:name>Isis Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6CEF6178-4F5D-4B21-BB3F-76C9E3CF4D3B"><gtr:id>6CEF6178-4F5D-4B21-BB3F-76C9E3CF4D3B</gtr:id><gtr:firstName>Edward</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wild</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM008592%2F1"><gtr:id>B7BA23DD-DF18-4903-B280-DD00B77D94E9</gtr:id><gtr:title>MICA: HD-CSF: Studying cerebrospinal fluid to understand key CNS pathobiological targets in Huntington's disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/M008592/1</gtr:grantReference><gtr:abstractText>Huntington's disease (HD) is a fatal, incurable inherited disease that causes brain degeneration and dementia. It is one of the commonest inherited causes of neurodegeneration and causes complex disability lasting around twenty years from onset to death. HD is always caused by a mutation that causes cells to produce a harmful protein called mutant huntingtin (mHTT).

The most promising experimental treatments being developed are drugs to reduce production of the mHTT protein that causes HD. This is called 'gene silencing' or 'huntingtin lowering'. Another promising approach is to develop drugs to restore the balance of protective and toxic chemicals produced by the brain's immune cells. These are known as kynurenine pathway or 'KP' metabolites and we know from animal models and post-mortem human brains that their balance is altered in HD in a way that seems to make the disease worse.

Cerebrospinal fluid (CSF) is a clear fluid, produced by the brain, which surrounds the brain and spinal cord, contains chemicals derived from the brain, and can be collected from living patients by a relatively straightforward procedure called lumbar puncture.

Developing huntingtin-lowering drugs would happen faster if we could measure how much mHTT is in the nervous system - then we would know if we have successfully lowered it. The same is true for KP metabolites and drugs to alter them. But nobody has ever measured CSF huntingtin levels, because the concentration is too low; and KP metabolites have never been accurately measured in HD patients.

We have developed an ultra-sensitive test to measure mutant huntingtin levels, using laser-activated counting of single huntingtin molecules labelled with newly-developed antibodies. Our pilot data show that this test can measure mHTT for the first time, in CSF from two different populations. What's more, the level of mHTT seems to increase as the disease progresses, meaning that it potentially serve as a 'biomarker' to predict progression or decide on the best time to treat patients with drugs in the future. We are working to develop tests that will mention the different chopped-up lengths of mHTT, to help figure out which are the most harmful ones.

We have also developed sensitive and reliable tests for KP metabolites, and we need good quality CSF to measure them in.

The 'HD-CSF' study will collect CSF and clinical data from 80 HD gene carriers and controls, twice each, two years apart, using methods designed to ensure the CSF is as pure and useful as possible. Poor quality CSF, and inconsistencies in handling and processing it, has been a problem with previous studies trying to use CSF to study HD.

Importantly, as well as CSF collection, HD-CSF participants will undergo detailed clinical and cognitive assessment, and MRI scanning to measure the rate of brain shrinkage. These assessments have been developed and proven to be of clinical relevance through our ground-breaking TRACK-HD study. The CSF and clinical and MRI data will be used to help us understand how mHTT levels and LP metabolites change as the disease progresses; and which chemical changes in CSF predict disease progression.

Measuring these chemicals in CSF using our ultra-sensitive tests will help understand how HD damages the brain, and provide new ways to measure its progression and, in future, whether a drug is having the desired effect, ultimately accelerating the development of treatments.</gtr:abstractText><gtr:technicalSummary>Huntington's disease (HD) is a fatal, autosomal dominantly inherited neurodegenerative disease causing motor and psychiatric symptoms and dementia. No disease-slowing treatment exists. HD is caused by an expanded CAG triplet repeat in HTT, resulting in mutant huntingtin protein (mHTT). Promising therapeutic candidates nearing human trials include nucleotide-based huntingtin-lowering drugs and kynurenine mono-oxygenase inhibitors.

Huntingtin has never been quantified in the living CNS, limiting our understanding of the role of wild-type and mutant HTT and their cleaved species in patients, and how these roles change over time; and preventing demonstration of target engagement by HTT-lowering drugs.

We have developed a novel, ultra-sensitive immunoassay which can quantify mHTT for the first time in patient CSF, completely distinguishing controls, premanifest mutation-carriers and patients. mHTT level correlates with neurofilament light chain, indicating likely neuronal origin.

Depending on the activity of KMO, the kynurenine pathway (KP) produces either neurotoxic or neuroprotective metabolites. It is deleteriously deranged in HD but has never been studied using accurate methods in patient CSF.

HD-CSF is the first comprehensive longitudinal study of CSF to elucidate key CNS pathobiological targets in HD. CSF, blood and robust phenotypic data including volumetric MRI will be collected from an 80-subject cohort at two timepoints. Samples will be analysed using our novel assays to quantify mHTT and KP metabolites and examine associations with disease progression. These core findings will be enriched through the targeted study of CNS-specific proteins in CSF. 

Comprehensive longitudinal study of KP metabolites and huntingtin species in patient CSF, linked to robust clinical and MRI atrophy data, will enhance our understanding of HD neuropathobiology in the living patient CNS, and provide pharmacodynamic biomarkers to accelerate therapeutic development.</gtr:technicalSummary><gtr:potentialImpactText>Through presentation of the results of this work in peer-reviewed articles and conference presentations, the academic beneficiaries will gain an increased understanding of the pathobiology of HD in the living patient CNS. This will benefit not only the global HD research community but also the broader neurodegenerative disease field, since HD can serve as a model for the earliest events in neurodegeneration.

HD-CSF will generate meaningful CSF biomarkers and an understanding of how those biomarkers predict progression. This will enable the efficient conduct of clinical trials through pharmacodynamic biomarkers of CNS huntingtin-lowering and KMO inhibition. More broadly, CSF HTT and kynurenine pathway metabolites may prove useful for stratification to determine which patients should enter clinical trials and when. The immediate beneficiaries of this will be industry-academic collaborations essential to the conduct of large-scale trials of disease-modifying therapies for HD. Patients and those at risk of HD will ultimately benefit through the accelerated development of disease-slowing therapeutics. Again, the applicability of these techniques beyond HD (especially given the involvement of the kynurenine pathway in many brain diseases) will benefit academia, industry and patients across neurodegeneration. Bringing pharma-funded clinical trials to the UK and to UCL will be financially advantageous to the UK economy and the UK academic sector's international reputation.

The biobank of CSF, collected longitudinally and rich phenotypic data including MRI that HD-CSF will generate will provide many opportunities for further research, primarily into HD but also to explore differences and similarities between HD and other brain diseases. The beneficiaries of this will be the researchers (including myself and future team members) whose work will be stimulated by this collection; UCL and the UK research community through attracting collaborations and funding; and the patient communities affected, through the discoveries that will emerge from this valuable resource.

HD-CSF may generate intellectual property through the identification of novel CSF pharmacodynamic and clinical biomarkers for Huntington's disease. This will enable clinical trials by identifying drug efficacy and consequently will be a valuable commercial tool of high interest to pharma companies. IP may come not only from the assays themselves, developed and tested in these samples, but their application to Huntington's disease and to detect a meaningful biological response to treatment with KMO inhibitors or HTT-lowering drugs. They will likely be of value in other neurodegenerative diseases such as Alzheimer's and Parkinson's. UCL Business PLC (UCLB) is the technology transfer company of UCL responsible for the management of UCL's intellectual property. Any IP that develops under the funded work at UCL will be appraised by UCLB for IP protection and, if appropriate, a patent application will be filed. UCLB will pay for the filing and the prosecution of the patent and will work with the MRC, GSK, CHDI Foundation and IRBM Promidis to identify appropriate routes to market.

The main motivation behind HD-CSF is to benefit the global community of HD patients and family members through accelerating the development of therapies for HD. Given the decades-long burden of complex physical, cognitive and behavioural disability that HD causes in every sufferer, and the psychological trauma to those at risk, the potential for benefits to the health of the nation are significant.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1078264</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>A physical performance piece aimed at introducing genetics and science to young (primary school) children. I was a scientific advisor.</gtr:description><gtr:id>6DFF219C-639F-49F0-B827-A8B7807F2D33</gtr:id><gtr:impact>Coverage in news media</gtr:impact><gtr:outcomeId>58b2cd234951e1.26272185</gtr:outcomeId><gtr:title>'Tree' - collaboration with Highly Sprung Performance Company</gtr:title><gtr:type>Performance (Music, Dance, Drama, etc)</gtr:type><gtr:url>http://www.highlysprungperformance.co.uk/tree</gtr:url><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK Kynurenine pathway</gtr:description><gtr:id>7FF06A9F-C946-42A2-A3CB-A53C7C558829</gtr:id><gtr:impact>Partnership agreed but no outputs yet</gtr:impact><gtr:outcomeId>meSAxRPhWfz-1</gtr:outcomeId><gtr:partnerContribution>Expertise, finance, KMO pathway assays and laboratory work</gtr:partnerContribution><gtr:piContribution>Conception and design of clinical translational study, collection and provision of CSF samples and clinical data, and analysis of data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CHDI Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Huntingtin quantification: CHDI / IRBM / BioFocus</gtr:description><gtr:id>3770DD93-1180-429B-981E-4DFB35F57EA5</gtr:id><gtr:impact>Paper in JCI 2012 (PMID 22996692).
Prize-winning poster presentation at international HD Therapeutics meeting 2013.</gtr:impact><gtr:outcomeId>o1kLPLjDwz4-1</gtr:outcomeId><gtr:partnerContribution>Our partners have supplied funding, assay development technology and reagents but the projects have been clinically led from UCL.</gtr:partnerContribution><gtr:piContribution>I have defined protocols and collected biosamples (blood and CSF) and phenotypic data to refine several generations of assays for mutant and total huntingtin protein and used them to study the pathobiology of Huntington's disease.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IRBM Promidis</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Huntingtin quantification: CHDI / IRBM / BioFocus</gtr:description><gtr:id>DD46925B-7C5D-4A5E-B016-0C6AC1ADC8F1</gtr:id><gtr:impact>Paper in JCI 2012 (PMID 22996692).
Prize-winning poster presentation at international HD Therapeutics meeting 2013.</gtr:impact><gtr:outcomeId>o1kLPLjDwz4-2</gtr:outcomeId><gtr:partnerContribution>Our partners have supplied funding, assay development technology and reagents but the projects have been clinically led from UCL.</gtr:partnerContribution><gtr:piContribution>I have defined protocols and collected biosamples (blood and CSF) and phenotypic data to refine several generations of assays for mutant and total huntingtin protein and used them to study the pathobiology of Huntington's disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Isis Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Isis Pharmaceuticals</gtr:description><gtr:id>F499639D-9357-4EF9-BAF9-1E8D98072207</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>5474aadc2ac2b4.36091354-1</gtr:outcomeId><gtr:partnerContribution>Partnership in developing trial protocol for antisense oligonucleotide huntington-lowering trial for Huntington's disease</gtr:partnerContribution><gtr:piContribution>Partnership (formal consultancy) in developing trial protocol for antisense oligonucleotide huntingtin-lowering trial for Huntington's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>California Institute of Technology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Biology and Biological Engineering (BBE)</gtr:department><gtr:description>Collaboration with Dr Ali Khoshnan (Caltech)</gtr:description><gtr:id>5C4C0E60-7BB7-41AE-951F-0363FDF6A55F</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58b2bdee844349.55364210-1</gtr:outcomeId><gtr:partnerContribution>Analysis and data on oligomers in CSF</gtr:partnerContribution><gtr:piContribution>Supply of samples to study oligomerisation in Huntington's disease CSF.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sangamo Biosciences, Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Consultancy with Sangamo / Shire</gtr:description><gtr:id>DAC2BEC6-1C5D-4AD1-8F58-420649635190</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>560d194b1c7958.98770951-1</gtr:outcomeId><gtr:partnerContribution>Shire and Sangamo are intending to run the trial</gtr:partnerContribution><gtr:piContribution>I am a consultant on the design of clinical trials of a zinc-finger transcriptional repressor drug for Huntington's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Education</gtr:department><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>11E607BD-4450-4EBC-83F0-7764731E2653</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-5</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre For Movement Disorders</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>8FCE5A88-B06E-438B-AC11-2CC3DE821329</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-7</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of British Columbia</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>CFBE47A6-0C7B-4D6B-B075-068CBB2E6EC4</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-2</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>15581D24-0D62-4B74-AD88-E17E1BF68149</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-8</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ulm University Medical Center</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>C078A395-00FA-4C69-99C3-6F03C6939C29</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-3</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neuroscience (GSK)</gtr:department><gtr:description>GSK: Advisory Board</gtr:description><gtr:id>957F3959-F217-41E7-A075-0D5B99D98080</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58b2b971af17b8.41391972-1</gtr:outcomeId><gtr:partnerContribution>GSK is developing the target</gtr:partnerContribution><gtr:piContribution>I am a member of an advisory board for GSK on a novel target in neurodegeneration (details confidential)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leverndale Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>E80FFA68-5D2D-4957-A424-986F7A6D9BF4</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-4</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, Los Angeles (UCLA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>UCLA Cardiac Arrhythmia Center</gtr:department><gtr:description>Collaboration with William Yang UCLA</gtr:description><gtr:id>92ED2993-0FB2-4676-BD75-845DEC6C0CD3</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58b2bc5b409864.61914782-1</gtr:outcomeId><gtr:partnerContribution>Assaying of CSF seeding (in progress)</gtr:partnerContribution><gtr:piContribution>CSF samples supplied to study huntingtin seeding in CSF</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biofocus</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Huntingtin quantification: CHDI / IRBM / BioFocus</gtr:description><gtr:id>05F611A7-F53A-4076-AFEE-AF862C5556E6</gtr:id><gtr:impact>Paper in JCI 2012 (PMID 22996692).
Prize-winning poster presentation at international HD Therapeutics meeting 2013.</gtr:impact><gtr:outcomeId>o1kLPLjDwz4-3</gtr:outcomeId><gtr:partnerContribution>Our partners have supplied funding, assay development technology and reagents but the projects have been clinically led from UCL.</gtr:partnerContribution><gtr:piContribution>I have defined protocols and collected biosamples (blood and CSF) and phenotypic data to refine several generations of assays for mutant and total huntingtin protein and used them to study the pathobiology of Huntington's disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wave Life Sciences</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:description>Wave Life Sciences: consultancy</gtr:description><gtr:id>5FF31B78-9585-4BB6-8C17-0B0122157030</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58b2b8f9be3e00.13587143-1</gtr:outcomeId><gtr:partnerContribution>Wave is the pharmaceutical company that is developing the assets and establishing the trial</gtr:partnerContribution><gtr:piContribution>I am a member of the Clinical Advisory Board to Wave Life Sciences, who are developing novel antisense therapies for Huntington's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, Irvine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Collaboration with Prof Leslie Thompson (UC Irvine)</gtr:description><gtr:id>5C788342-60B2-4616-864B-A69A244E4EB2</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58b2bcd7cf9635.64546085-1</gtr:outcomeId><gtr:partnerContribution>Data and analysis of exosomes</gtr:partnerContribution><gtr:piContribution>Supply of samples to study exosomes in CSF</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Gothenburg</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Pathology and Genetics</gtr:department><gtr:description>Collaboration with University of Gothenberg (Zetterberg)</gtr:description><gtr:id>9AE67D40-613C-40F7-82BD-02972D3B1BA6</gtr:id><gtr:impact>3 publications so far:
Wild et al JCI 2015
Rodrigues et al PLoS One 2016
Rodrigues et al J Neurochem 2016</gtr:impact><gtr:outcomeId>58b2bbb54a8ff0.11789723-1</gtr:outcomeId><gtr:partnerContribution>Expertise and resources in assaying CSF biomarkers</gtr:partnerContribution><gtr:piContribution>Samples, data, analysis of results. Collaboration to quantify CSF biomarkers for Huntington's disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Consultancy with Roche</gtr:description><gtr:id>C529B508-05B6-4F8A-8974-9DA0C7786B7D</gtr:id><gtr:impact>Collaboration likely to secure my role in design and conduct of groundbreaking trials</gtr:impact><gtr:outcomeId>56deace10af809.23467419-1</gtr:outcomeId><gtr:partnerContribution>Roche intends to run the next trial</gtr:partnerContribution><gtr:piContribution>Consultancy on design of future gene-silencing trials in Huntington's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lisbon</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:department>Institute for Molecular Medicine</gtr:department><gtr:description>University of Lisbon (Prof Joaquim Ferreira)</gtr:description><gtr:id>CA38AE54-B4D9-4870-979D-2946FC91BC49</gtr:id><gtr:impact>In-press publication in Movement Disorders Clinical Practice (Rodrigues et al 2017)</gtr:impact><gtr:outcomeId>58b2bf8c139524.40054468-1</gtr:outcomeId><gtr:partnerContribution>Expertise (Prof Ferreira and his partners are members of the Cochrane Collaboration)</gtr:partnerContribution><gtr:piContribution>Under my supervision, my Clinical Fellow Filipe Rodrigues established this partnership and we have worked together on multiple meta-analysis projects in Huntington's disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shire Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Consultancy with Sangamo / Shire</gtr:description><gtr:id>7D056B60-F8E0-466E-92D6-B83145B096FF</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>560d194b1c7958.98770951-2</gtr:outcomeId><gtr:partnerContribution>Shire and Sangamo are intending to run the trial</gtr:partnerContribution><gtr:piContribution>I am a consultant on the design of clinical trials of a zinc-finger transcriptional repressor drug for Huntington's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CHDI Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>8309FF8B-6D1D-4BC6-B6A4-AF0A7EFAFF48</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-1</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>RAND Boston</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>RAND Corporation (causal modelling in HD)</gtr:description><gtr:id>B74AEA94-11B0-48FF-B739-59BAD3408B51</gtr:id><gtr:impact>Funding from CHDI Foundation to RAND corporation.</gtr:impact><gtr:outcomeId>58b2beca5d3b04.65028906-1</gtr:outcomeId><gtr:partnerContribution>Conduct of statistical analysis.</gtr:partnerContribution><gtr:piContribution>Design of protocol, application for funding to CHDI Foundation; ongoing intellectual input. Study using causal modelling to identify factors influencing the onset of Huntington's disease.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CHDI Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CHDI Foundation: study of kynurenine pathway</gtr:description><gtr:id>AA58BADB-FBA7-40BF-9E2A-AC3837E54BA1</gtr:id><gtr:impact>Oral presentation at CHDI Foundation Annual Therapeutics conference in 2015.
Oral presentation at Hereditary Disease Foundation Biennial meeting in 2016.</gtr:impact><gtr:outcomeId>58b2bd57044538.56468436-1</gtr:outcomeId><gtr:partnerContribution>Analysis of KP metabolites (ongoing)</gtr:partnerContribution><gtr:piContribution>Supply of expertise and samples for studying the kynurenine pathway in HD</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Chemical and Biomolecular Engineering</gtr:department><gtr:description>CHDI Foundation: global CI of HDClarity study</gtr:description><gtr:id>42DF916A-C7ED-43CC-819B-CF604AA018CA</gtr:id><gtr:impact>Oral presentation at the European Huntington's Disease Network Plenary Meeting, September 2016.
Oral presentation at the Hereditary Disease Foundation biennial meeting, August 2016.</gtr:impact><gtr:outcomeId>560d1861d41593.17707933-6</gtr:outcomeId><gtr:partnerContribution>CHDI is the funder (3 staff members at UCL - Trial manager, Research Administrator and Clinical Fellow) and provides infrastructural support and direct funding to clinical sites (total value estimated at &amp;pound;3m). Other sites listed are clinical sites either active or under enrolment.</gtr:partnerContribution><gtr:piContribution>On the basis of my research to date in CSF biomarkers for Huntington's disease I was selected as the global CI of a new multi-site study, HDClarity. This aims to enrol up to 30 sites globally and produce the largest collection of CSF to date. It is highly complimentary to the work of my MRC Fellowship but places me at the centre of CSF research in HD globally. Sample collection is now underway at 2 sites beyond UCL (Vancouver and Glasgow).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Third-party article about my HDBuzz project in Journal of Huntington's Disease</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AFB31B2D-0555-4D8B-A85E-D712638FBAA1</gtr:id><gtr:impact>The Huntington's Disease Society of America wrote an article for the Journal of Huntington's Disease in which my HDBuzz outreach project was described and praised.</gtr:impact><gtr:outcomeId>58b2c78915ba28.87932407</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://dx.doi.org/10.3233/JHD-160230</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hereditary Disease Foundation Gala</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E4CDF263-B81B-4786-BBB8-7F606676B158</gtr:id><gtr:impact>Invited keynote lecture to a Fundraising Gala for the Hereditary Disease Foundation at the Metropolitan Club, New York City. The event raised $2m for Huntington's disease research.</gtr:impact><gtr:outcomeId>58b2c9272cc513.17449146</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.newyorksocialdiary.com/party-pictures/2016/celebrating-the-neighborhood</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Huntington Society of Canada - keynote lecture at annual convention</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>99A4F5A0-247D-4AF9-ACF9-13AA1885BB08</gtr:id><gtr:impact>Invited keynote lecture to the Annual Convention of the Huntington Society of Canada Biennial Convention - Halifax, 2016</gtr:impact><gtr:outcomeId>58b2c839d6ded0.00396011</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://huntingtonsociety.ca</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release and media relating to JCI 2015 paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C5F2B865-F6D2-49A2-B1E3-6F0B55F2C4F1</gtr:id><gtr:impact>Press release about my JCI 2015 paper which was picked up by several news outlets including Nature Reviews Neurology as a Research Highlight

Many people were made aware of my research</gtr:impact><gtr:outcomeId>560d1ac37c5ac9.44192054</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.nature.com/nrneurol/journal/v11/n5/full/nrneurol.2015.63.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>WIRED</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4A2924BB-E354-4AB2-9C1C-F449C23AD910</gtr:id><gtr:impact>Interview with WIRED magazine about CRISPR/Cas9</gtr:impact><gtr:outcomeId>58b2c5cc2398e1.72030309</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.wired.co.uk/article/crispr-cas9-technique-explained</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New Scientist</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C68E195-1004-4817-A91E-21C5985ED7DE</gtr:id><gtr:impact>Interview about Huntington's disease &amp;quot;gene silencing&amp;quot; trial in New Scientist, published 6th October 2016</gtr:impact><gtr:outcomeId>58b2c545eaf498.36522249</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.newscientist.com/article/mg23230943-300-children-with-fatal-muscle-disease-walk-after-drug-breakthrough/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Huntington's Disease Society of America - keynote lecture at annual convention</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2B9C82F3-4CA5-4D22-BF74-399B26AF4322</gtr:id><gtr:impact>Invited keynote lecture to the Huntington's Disease Society of America annual convention, Baltimore, June 2016</gtr:impact><gtr:outcomeId>58b2c7efb2f904.73448390</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://hdsa.org</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC / Telegraph / Times - news coverage of Huntington's disease trial</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2E6A40C9-1B9B-4A4E-A456-0124014CD522</gtr:id><gtr:impact>Extensive news media coverage of the start of our clinical trial (sponsored by Ionis pharmaceuticals) of the first Huntington's disease gene silencing treatment.</gtr:impact><gtr:outcomeId>58b2c697af6e26.22151442</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-34552041</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 - Women's Hour</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>65EF8D3E-80A7-4162-A316-E13997339F9D</gtr:id><gtr:impact>Interview with Jenni Murray about Huntington's disease, broadcast on BBC Radio 4 Woman's Hour on 15th July 2016</gtr:impact><gtr:outcomeId>58b2c4d7eb1775.65208843</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b07jqr4j</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Pint of Science' festival 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A9A7B689-A93E-4711-9099-AB463C2594BD</gtr:id><gtr:impact>Public lecture on my research to the Pint of Science festival, widely attended and open to the public</gtr:impact><gtr:outcomeId>56deb0472ab592.91465150</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://pintofscience.com</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HDBuzz</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>183C5F38-D27F-4D2F-A95C-CDB8F5E13637</gtr:id><gtr:impact>HDBuzz, a registered charity, is an online source of reliable, impartial, easy-to-understand information about Huntington's Disease research. I have assembled a team of 17 scientists to serve as writers, and 99 volunteers to translate content into 12 languages. HDBuzz is now the world's foremost HD research news source, receiving ~100,000 unique visitors per month and supplying HD research news to all the world's main HD websites.

HDBuzz has dramatically raised my profile among the global HD community of affected family members as well as scientists. As a result I am regularly invited to give keynote lectures at national and international patient meetings. It has also raised my personal profile among scientist colleagues through networking and recognition. We now support and award the 'HDBuzz Prize for Scientific Writing' annually.</gtr:impact><gtr:outcomeId>YauNk4w6JVJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://hdbuzz.net</gtr:url><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHDI Foundation: HDClarity Central Coordination</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>8012CA92-2FEC-43CA-AD7C-A7A008C84467</gtr:id><gtr:outcomeId>560d19aa626766.26078119</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56858</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHDI Foundation Clinical Fellowship</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>FF7F658B-0448-42E4-A1B7-352807DFA535</gtr:id><gtr:outcomeId>5474a1ddc2e760.47196444</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>29882</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Multi-User Equipment Award</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>108457/Z/15/Z</gtr:fundingRef><gtr:id>CF1684E2-CB73-4800-B833-FEA63855AFA2</gtr:id><gtr:outcomeId>58b2c3e7447ed8.05837470</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Single-molecule immunoassay for quantifying mutant huntingtin. The concentration of mutant huntingtin in CSF is an independent predictor of clinical phenotype in HD (Wild et al JCI 2015). The method is undergoing validation to FDA / EMA standards for clinical trial use (manuscript in draft).</gtr:description><gtr:id>F498B044-F0CE-443A-A484-4540E4235F9C</gtr:id><gtr:impact>Method is being used in a clinical trial</gtr:impact><gtr:outcomeId>58b2cc83a627a5.52248950</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Quantification of mutant huntingtin in CSF</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://dx.doi.org/10.1172/JCI80743</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Optimised protocol for the collection and processing of cerebrospinal fluid in Huntington's disease and other neurodegenerative disorders</gtr:description><gtr:id>7088D7D7-89D7-47BA-AF47-4F70880F36EA</gtr:id><gtr:impact>Multi-site HDClarity study - I am the global CI</gtr:impact><gtr:outcomeId>58b2cb599249c2.72333966</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Optimised methodology for the collection and processing of cerebrospinal fluid in Huntington's disease</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://hdclarity.net/study-information/</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Novel single molecule counting immunoassay to quantify mutant huntingtin protein in cerebrospinal fluid.</gtr:description><gtr:id>AE6A92D6-6CC3-4494-BF59-AC8FF4D383E3</gtr:id><gtr:impact>Publication in JCI 2015 (Wild et al)
Huntington Study Group &amp;quot;Insight of the Year&amp;quot; award 2015
Use of assay in Ionis clinical trial of huntingtin-lowering therapeutic</gtr:impact><gtr:outcomeId>58b2caf8aa5dd0.44109301</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Quantification of mutant huntingtin using single-molecule counting</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>https://www.jci.org/articles/view/80743</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FBA30048-287D-4FB5-9F28-0D39CF036998</gtr:id><gtr:title>Meta-research metrics matter: letter regarding article &amp;quot;indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Journal of clinical movement disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd80e09e39e33140492c6a9c2603025"><gtr:id>cfd80e09e39e33140492c6a9c2603025</gtr:id><gtr:otherNames>Rodrigues FB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2054-7072</gtr:issn><gtr:outcomeId>5a7de014d0a670.32984817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE5C5670-9A70-48F5-AF27-37FADFE97C9F</gtr:id><gtr:title>Neurofilament light protein in blood predicts regional atrophy in Huntington disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/857c42fb5eb62fac1fd3ba85ccb3e671"><gtr:id>857c42fb5eb62fac1fd3ba85ccb3e671</gtr:id><gtr:otherNames>Johnson EB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a7de014680cb6.92770118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D443A7B7-BF53-4DC7-AC59-7B3E3D8D8F0C</gtr:id><gtr:title>Clinical manifestations of intermediate allele carriers in Huntington disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d97bfaca7a48a5ef06907b282e52eac1"><gtr:id>d97bfaca7a48a5ef06907b282e52eac1</gtr:id><gtr:otherNames>Cubo E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a7de0162fd2c1.28980034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E389C87-F23A-407E-902F-AD806CD9615C</gtr:id><gtr:title>Cerebrospinal Fluid Biomarkers for Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c510a68ad4f0673409ed1de61aa2801"><gtr:id>2c510a68ad4f0673409ed1de61aa2801</gtr:id><gtr:otherNames>Byrne LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn><gtr:outcomeId>58b2b566966c04.70630009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6443C56F-E821-4384-8383-6D58C57ABC0C</gtr:id><gtr:title>Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/244cc363f830eda2f51ecf6bac87f6f0"><gtr:id>244cc363f830eda2f51ecf6bac87f6f0</gtr:id><gtr:otherNames>Hensman Moss DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a7de014a38f94.57550798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7064C822-C257-4074-AF50-E92CA9B6B901</gtr:id><gtr:title>Ghost Pills</gtr:title><gtr:parentPublicationTitle>Annals of Internal Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83fb7847f532aa9e93a8a5efbeb18e29"><gtr:id>83fb7847f532aa9e93a8a5efbeb18e29</gtr:id><gtr:otherNames>Taylor R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b2c2c8e88634.42474352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5224AC3E-BA1D-48D0-A845-11C981739351</gtr:id><gtr:title>Psychogenic non-epileptic seizures in early Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd80e09e39e33140492c6a9c2603025"><gtr:id>cfd80e09e39e33140492c6a9c2603025</gtr:id><gtr:otherNames>Rodrigues FB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>58b2b5661db2a0.49321812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD09237D-0DE4-48A9-ABEB-8B8A4E3EF4DF</gtr:id><gtr:title>Neuropsychiatry and White Matter Microstructure in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/089465fdee6ce32f4c3e04ff20830e80"><gtr:id>089465fdee6ce32f4c3e04ff20830e80</gtr:id><gtr:otherNames>Gregory S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn><gtr:outcomeId>58b2b566c4bd09.35576429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1157995A-3D6D-4179-B438-582F0FD97CC4</gtr:id><gtr:title>Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd80e09e39e33140492c6a9c2603025"><gtr:id>cfd80e09e39e33140492c6a9c2603025</gtr:id><gtr:otherNames>Rodrigues FB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58b2b5a94c75b9.34597318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>440436F6-97CA-45BA-B965-DF4AEB3159AD</gtr:id><gtr:title>Huntington's Disease: The Most Curable Incurable Brain Disorder?</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2ad55e1a2ad1526b8ced1a4945eda9d"><gtr:id>c2ad55e1a2ad1526b8ced1a4945eda9d</gtr:id><gtr:otherNames>Wild EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>58b2b56672f292.16744576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93F034B6-8B78-45A4-9AC9-36F5E49D6E43</gtr:id><gtr:title>Clinical Trials Corner: September 2017.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd80e09e39e33140492c6a9c2603025"><gtr:id>cfd80e09e39e33140492c6a9c2603025</gtr:id><gtr:otherNames>Rodrigues FB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn><gtr:outcomeId>5a7de0158c6e80.11532854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>574393BC-9B2D-48EB-8F21-EFAC0893606F</gtr:id><gtr:title>Huntington disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Disease primers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a6d340b1c9dd22889424ee21a45141"><gtr:id>46a6d340b1c9dd22889424ee21a45141</gtr:id><gtr:otherNames>Bates GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2056-676X</gtr:issn><gtr:outcomeId>560d15fb16c435.04139711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>022D916D-A19D-4145-BDFC-D118CA34359D</gtr:id><gtr:title>Therapies targeting DNA and RNA in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2ad55e1a2ad1526b8ced1a4945eda9d"><gtr:id>c2ad55e1a2ad1526b8ced1a4945eda9d</gtr:id><gtr:otherNames>Wild EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>5a7de015405293.49128328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABA2AE79-8946-4AD3-BE8E-946C5E9DB7C2</gtr:id><gtr:title>Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c510a68ad4f0673409ed1de61aa2801"><gtr:id>2c510a68ad4f0673409ed1de61aa2801</gtr:id><gtr:otherNames>Byrne LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa39b7d709bd1.34616665</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DD6E31C-E1C1-4F66-915D-01FF6427E0AE</gtr:id><gtr:title>Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c510a68ad4f0673409ed1de61aa2801"><gtr:id>2c510a68ad4f0673409ed1de61aa2801</gtr:id><gtr:otherNames>Byrne LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>5a7de01567d238.26483062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E51101B-D755-4A29-B2B0-B73742D6E63D</gtr:id><gtr:title>Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81c98ba7a1b05e7103fad6f8a0c28985"><gtr:id>81c98ba7a1b05e7103fad6f8a0c28985</gtr:id><gtr:otherNames>Fodale V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn><gtr:outcomeId>5a7de0151b95c6.61673934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A99D31B-5B74-43E0-800E-834C4BE621F9</gtr:id><gtr:title>Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?</gtr:title><gtr:parentPublicationTitle>Movement disorders clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd80e09e39e33140492c6a9c2603025"><gtr:id>cfd80e09e39e33140492c6a9c2603025</gtr:id><gtr:otherNames>Rodrigues FB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2330-1619</gtr:issn><gtr:outcomeId>58b2c1e99e6ad8.22840715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36DF2212-93C8-4CE5-8EB7-C2A8F1AD3334</gtr:id><gtr:title>George Huntington: a legacy of inquiry, empathy and hope.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5646aadd8bdfb2008e4164564bda1789"><gtr:id>5646aadd8bdfb2008e4164564bda1789</gtr:id><gtr:otherNames>Wexler A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58b2b5a913e960.63102278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3895E7DC-D25B-48E6-8D2E-5CD57D1006D1</gtr:id><gtr:title>Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2ad55e1a2ad1526b8ced1a4945eda9d"><gtr:id>c2ad55e1a2ad1526b8ced1a4945eda9d</gtr:id><gtr:otherNames>Wild EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>560d15fa5432d0.00180871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E14620AF-D714-49CE-AC9F-890CEA8122E9</gtr:id><gtr:title>Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd80e09e39e33140492c6a9c2603025"><gtr:id>cfd80e09e39e33140492c6a9c2603025</gtr:id><gtr:otherNames>Rodrigues FB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>58b2b56645dfc0.76313195</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M008592/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>